Kala Pharmaceuticals Announces IND Submission Of Its MPP-Formulated Loteprednol Etonbonate (LE-MPP) For Post-Cataract Surgery

Published: Jan 06, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the Company’s proprietary Mucus Penetrating Particle (MPP) technology, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to initiate a Phase 3 clinical program with its MPP-formulated loteprednol etabonate ophthalmic nano-suspension product (LE-MPP) for the treatment of post-operative inflammation and pain following cataract surgery.

Help employers find you! Check out all the jobs and post your resume.

Back to news